EA202192032A1 - Соединения n-ацил-{4-[(4-арилфенил)сульфонилметил]пиперидина} и их терапевтическое применение - Google Patents

Соединения n-ацил-{4-[(4-арилфенил)сульфонилметил]пиперидина} и их терапевтическое применение

Info

Publication number
EA202192032A1
EA202192032A1 EA202192032A EA202192032A EA202192032A1 EA 202192032 A1 EA202192032 A1 EA 202192032A1 EA 202192032 A EA202192032 A EA 202192032A EA 202192032 A EA202192032 A EA 202192032A EA 202192032 A1 EA202192032 A1 EA 202192032A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
relates
arylphenyl
sulfonylmethyl
acyl
Prior art date
Application number
EA202192032A
Other languages
English (en)
Inventor
Лиза Пейтел
Стивен Аллан Смит
Стивен Пол Коллингвуд
Original Assignee
Модерн Биосайенсес Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Модерн Биосайенсес Лимитед filed Critical Модерн Биосайенсес Лимитед
Publication of EA202192032A1 publication Critical patent/EA202192032A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/24—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

В целом изобретение относится к области терапевтических соединений. Более конкретно, настоящее изобретение относится к определенным соединениям N-ацил-{4-[(4-арилфенил)сульфонилметил]пиперидина} следующей формулы (в совокупности называемым в настоящем документе соединениями NASMP), которые полезны, например, при лечении расстройств (например, заболеваний), включая, например, множественную миелому, диффузную крупноклеточную В-клеточную лимфому, острый миелоидный лейкоз, эозинофильный лейкоз, глиобластому, меланому, рак яичника, резистентный к химиотерапии рак, резистентный к лучевой терапии рак, воспалительный артрит, ревматоидный артрит, псориатический артрит, псориаз, язвенный колит, болезнь Крона, системную красную волчанку (СКВ), волчаночный нефрит, астму, хроническую обструктивную болезнь легких (ХОБЛ), гнойный гидраденит, аутоиммунный гепатит и т.д. Настоящее изобретение также относится к фармацевтическим композициям, содержащим такие соединения, и к применению таких соединений и композиций, например, в терапии.
EA202192032A 2019-04-18 2020-04-17 Соединения n-ацил-{4-[(4-арилфенил)сульфонилметил]пиперидина} и их терапевтическое применение EA202192032A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1905520.1A GB201905520D0 (en) 2019-04-18 2019-04-18 Compounds and their therapeutic use
PCT/EP2020/060879 WO2020212581A1 (en) 2019-04-18 2020-04-17 N-acyl-{4-[(4-aryl-phenyl)sulfonylmethyl]piperidine} compounds and their therapeutic use

Publications (1)

Publication Number Publication Date
EA202192032A1 true EA202192032A1 (ru) 2022-03-10

Family

ID=66810170

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202192032A EA202192032A1 (ru) 2019-04-18 2020-04-17 Соединения n-ацил-{4-[(4-арилфенил)сульфонилметил]пиперидина} и их терапевтическое применение

Country Status (16)

Country Link
US (1) US20230022917A1 (ru)
EP (1) EP3956030A1 (ru)
JP (1) JP2022528799A (ru)
KR (1) KR20220002871A (ru)
CN (1) CN113766953A (ru)
AU (1) AU2020257561A1 (ru)
BR (1) BR112021016672A2 (ru)
CA (1) CA3132265C (ru)
EA (1) EA202192032A1 (ru)
GB (1) GB201905520D0 (ru)
IL (1) IL287279A (ru)
MA (1) MA55713A (ru)
MX (1) MX2021012743A (ru)
SG (1) SG11202109734SA (ru)
WO (1) WO2020212581A1 (ru)
ZA (1) ZA202106236B (ru)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753679A (en) 1995-05-10 1998-05-19 Hoffmann-La Roche Inc. Benzyl-piperidine derivatives
EP1265863A1 (en) * 2000-03-21 2002-12-18 The Procter & Gamble Company Heterocyclic side chain containing metalloprotease inhibitors
AU2002357312A1 (en) 2001-12-20 2003-07-09 Bristol-Myers Squibb Company Barbituric acid derivatives as inhibitors of tnf-alpha converting enzyme (tace) and/or matrix metalloproteinases
EP2527337A1 (en) 2005-04-14 2012-11-28 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
AU2006264649A1 (en) 2005-06-30 2007-01-11 Prosidion Limited GPCR agonists
US20090069304A1 (en) 2006-03-03 2009-03-12 Shionogi & Co., Ltd. Mmp-13 selective inhibitor
PE20080932A1 (es) 2006-11-10 2008-07-13 Wyeth Corp Piperidinil 4-arilsulfonamidas n-sustituidas como moduladores de la proteina 1 secretada relacionada con frizzled (sfrp-1)
EP2325182A1 (en) 2006-12-06 2011-05-25 Glaxosmithkline LLC Bicyclic compounds and use as antidiabetics
WO2009020140A1 (ja) 2007-08-06 2009-02-12 Dainippon Sumitomo Pharma Co., Ltd. アダマンチルウレア誘導体
EP2205083B1 (en) 2007-10-04 2013-07-17 Merck Sharp & Dohme Corp. Substituted aryl sulfone derivatives as calcium channel blockers
GB0817208D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd Therapeutic apsap compounds and their use
GB0817207D0 (en) * 2008-09-19 2008-10-29 Pimco 2664 Ltd therapeutic apsac compounds and their use
IN2014MN02380A (ru) 2012-06-12 2015-08-14 Chong Kun Dang Pharm Corp
KR20150126901A (ko) 2013-03-06 2015-11-13 에프. 호프만-라 로슈 아게 항바이러스성 화합물
GB201311361D0 (en) * 2013-06-26 2013-08-14 Pimco 2664 Ltd Compounds and their therapeutic use
US10005733B2 (en) * 2014-12-17 2018-06-26 Pimco 2664 Limited N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)-benzenesulfonamide compounds and their therapeutic use
KR20230145504A (ko) 2015-01-22 2023-10-17 미요카디아, 인크. 확장성 심근병증 (dcm)의 치료를 위한 4-메틸술포닐-치환된 피페리딘 우레아 화합물

Also Published As

Publication number Publication date
IL287279A (en) 2021-12-01
WO2020212581A1 (en) 2020-10-22
GB201905520D0 (en) 2019-06-05
JP2022528799A (ja) 2022-06-15
CA3132265C (en) 2023-12-19
BR112021016672A2 (pt) 2021-10-13
MA55713A (fr) 2022-02-23
SG11202109734SA (en) 2021-10-28
US20230022917A1 (en) 2023-01-26
KR20220002871A (ko) 2022-01-07
CN113766953A (zh) 2021-12-07
EP3956030A1 (en) 2022-02-23
AU2020257561A1 (en) 2021-10-28
MX2021012743A (es) 2021-11-17
ZA202106236B (en) 2023-05-31
CA3132265A1 (en) 2020-10-22

Similar Documents

Publication Publication Date Title
NI200500118A (es) Derivados de 3-(3,5-dioxo-4,5-dihidro-3h-(1,2,4) triazin-2-il)-benzamida como inhibidores de p2x7 para el tratamiento de enfermedades inflamatorias.
NZ742476A (en) Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
MA20150290A1 (fr) Composés hétéroromatiques en tant qu'inhibiteurs de la tyrosine kinase de bruton (btk)
PH12018500533A1 (en) Pyrazolyl-substituted heteroaryls and their use as medicaments
IN2012CH01573A (ru)
DE602004005033D1 (de) Benzamidinhibitoren des p2x7-rezeptors
EA201492250A1 (ru) Гетероциклическое соединение
BR112015017338A2 (pt) anticorpos anti-il-17a e seu uso no tratamento de transtornos autoimunes e inflamatórios
AR054084A1 (es) Derivados de indolcarboxamida y composiciones farmaceuticas que los contienen
TR201814710T4 (tr) Yeni Geliştirilmiş Değişik Halkalı Heterosiklik Türevler Ve Bunların Kullanımı
CY1112370T1 (el) Παραγωγα σουλφοναμιδης και χρηση αυτων στη ρυθμιση των μεταλλοπρωτεϊνασων
MA37439B1 (fr) Inhibiteurs de dgat1 à ponts éthers cycliques pour le traitement de troubles medies par l'acyle coa-diacylglycerol transferase 1 (dgat1).
NO20070994L (no) N-hydroksamid derivater og anvendelse derav
RU2008143557A (ru) Тиазолилдигидроиндазолы
MX2020014156A (es) Oxadiazoles como agonistas de los receptores muscarinicos m1 y/o m4.
MX363658B (es) N-(4-(azaindazol-6-il)-fenil)-sulfonamidas y su uso como productos farmacéuticos.
EA202092678A1 (ru) 1,3-тиазол-2-ил-замещенные бензамиды для лечения заболеваний, ассоциированных с сенситизацией нервных волокон
MX2019008626A (es) Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-ilcarbamato como inhibidores de monoacilglicerol lipasa (magl).
EA201491622A1 (ru) Биспецифические антитела против baff и ил-17
PH12017501428A1 (en) 4-substituted benzoxaborole compounds and uses thereof
EA201791367A1 (ru) Соединения 2,3,4,5-тетрагидропиридин-6-амин и 3,4-дигидро-2h-пиррол-5-амин - ингибиторы бета-секретазы
EA202192905A1 (ru) Соединения, содержащие n-метил-2-пиридон, и фармацевтически приемлемые соли
EA201591881A1 (ru) Гетероциклическое соединение
JP2019501927A5 (ru)
CY1119438T1 (el) Ν-(4-υδροξυ-4-μεθυλ-κυκλοεξυλ)-4-φαινυλ-βενζολοσουλφοναμιδια και ν-(4-υδροξυ-4-μεθυλ-κυκλοεξυλ)-4-(2-πυριδυλ)βενζολοσουλφοναμιδια και η θεραπευτικη τους χρηση